Cabozantinib
Other name
-
International/Other brands
Cabometyx
Groups
Approved
Structure
Prescription products
| Name | Dosage | Strength | Route | Labeller |
|---|---|---|---|---|
| Cabometyx | Tablet | 40 mg/1 | Oral | Exelixis |
| Cabometyx | Tablet | 20 mg/1 | Oral | Exelixis |
| Cabometyx | Tablet | 60 mg/1 | Oral | Exelixis |
| Cometriq | Capsule | 20 mg/1 | Oral | Exelixis |
| Cometriq | Capsule | 20 mg | Oral | Tmc Pharma Services Ltd. |
| Cometriq | Kit | - | - | Exelixis |
Target
Description
Cabozantinib was approved in 2012 and is a non-specific tyrosine kinase inhibitor. It is marketed as Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. It's label includes a black box warning of gastrointestinal perforations, fistulas, and hemorrhage. The FDA approved cabozantinib as Cabometyx for patients with advanced renal cell carcinoma in April 2016.
Indications
Advanced Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer
Other indications
-
Mechaism of action
-
Absorption
After oral administration, peak plasma concentration was achieved in 2-5 hours.
Metabolism
Cabozantinib is metabolized mostly by CYP3A4 and, to a minor extent, by CYP2C9. Both enzyme produce an N-oxide metabolite.
Toxicity
Cabozantinib has a black box warning of serious gastrointestinal fistulas and perforations, and potentially fatal hemoptysis and gastrointestinal hemorrhage.